Skip to main content

Medline Inc. (MDLN) Stock Analysis

SellVALUE-TRAP 1/5Moderate Confidence

Healthcare · Medical Instruments & Supplies

Earnings in 6 days (2026-05-06). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Momentum 2.7/10 is below the 5.0 floor at $44.00 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: largest GPOs (69.0%); Concentration risk — Customer: Prime Vendor agreements (63.4%).

Medline is the largest provider of med-surg products and supply chain solutions, distributing approximately 335,000 products through Medline Brand and Supply Chain Solutions segments to hospitals and all care settings. Active Prime Vendor agreements generated approximately 63.4%... Read more

$44.00+11.0% A.UpsideScore 5.1/10#18 of 25 Medical Instruments & Supplies
Stop $41.11Target $48.17(analyst − 10%)A.R:R 1.6:1
Analyst target$53.52+21.6%27 analysts
$48.17our TP
$44.00price
$53.52mean
$60

Sell if holding. Momentum 2.7/10 is below the 5.0 floor at $44.00 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: largest GPOs (69.0%); Concentration risk — Customer: Prime Vendor agreements (63.4%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.1/10, moderate confidence.

Passes 4/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and news soft fda negative and earnings proximity 6d<=7d. Suitability: moderate.

Thesis

Rewards
No bull case signals
Risks
Concentration risk — Customer: largest GPOs (69.0%)
Concentration risk — Customer: Prime Vendor agreements (63.4%)
Earnings in 6 days (event risk)

Key Metrics

P/E (TTM)30.3
P/E (Fwd)26.2
Mkt Cap$36.7B
EV/EBITDA17.2
Profit Mgn4.1%
ROE6.5%
Rev Growth14.8%
Beta
DividendNone
Rating analysts33

Quality Signals

Piotroski F8/9

Options Flow

P/C0.44bullish
IV78%elevated
Max Pain$20-54.5% vs spot

Concentration Risks(10-K Item 1A)

  • HIGHCustomerlargest GPOs69%
    10-K Item 1A: '69% of consolidated net sales...our largest GPOs: Vizient Supply, LLC, HealthTrust Purchasing Group, L.P., and Premier Healthcare Alliance, L.P.'
  • HIGHCustomerPrime Vendor agreements63%
    10-K Item 1A: 'Our active Prime Vendor agreements as of December 31, 2025 generated approximately 63.4% ($18.0 billion) of net sales'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

1 floor-breaker

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Ma Position
2.5
Rsi
3.5
Volume
6.7
Volume distribution (falling OBV)
GatesMomentum 2.7<4.5NEWS SOFT FDA NEGATIVEEARNINGS PROXIMITY 6d<=7dA.R:R 1.6 ≥ 1.5Insider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARSuitability: Moderate
RSI
39 · Neutral
20D MA 50D MA 200D MASupport $42.38Resistance $49.13

Price Targets

$41
$48
A.Upside+9.5%
A.R:R1.6:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Momentum score 2.7/10 — below 4.5 minimum
! NEWS_SOFT:FDA_NEGATIVE
! EARNINGS_PROXIMITY:6d<=7d

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-05-06 (6d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is MDLN stock a buy right now?

Sell if holding. Momentum 2.7/10 is below the 5.0 floor at $44.00 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Customer: largest GPOs (69.0%); Concentration risk — Customer: Prime Vendor agreements (63.4%). Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $41.11. Score 5.1/10, moderate confidence.

What is the MDLN stock price target?

Take-profit target: $48.17 (+11.0% upside). Prior stop was $41.11. Stop-loss: $41.11.

What are the risks of investing in MDLN?

Concentration risk — Customer: largest GPOs (69.0%); Concentration risk — Customer: Prime Vendor agreements (63.4%); Earnings in 6 days (event risk).

Is MDLN overvalued or undervalued?

Medline Inc. trades at a P/E of 30.3 (forward 26.2). TrendMatrix value score: 6.2/10. Verdict: Sell.

What do analysts say about MDLN?

33 analysts cover MDLN with a consensus score of 4.2/5. Average price target: $54.

What does Medline Inc. do?Medline is the largest provider of med-surg products and supply chain solutions, distributing approximately 335,000...

Medline is the largest provider of med-surg products and supply chain solutions, distributing approximately 335,000 products through Medline Brand and Supply Chain Solutions segments to hospitals and all care settings. Active Prime Vendor agreements generated approximately 63.4% of 2025 net sales, with 69% of consolidated net sales from hospitals under contracts with Vizient, HealthTrust, and Premier GPOs.

Related stocks: WST (West Pharmaceutical Services, I) · ISRG (Intuitive Surgical, Inc.) · MMSI (Merit Medical Systems, Inc.) · STVN (Stevanato Group S.p.A.) · RMD (ResMed Inc.)